PR85 OUR TREATMENT STRATEGY FOR PATIENTS WITH HORMONE-RECEPTOR-POSITIVE, HER2-POSITIVE METASTATIC BREAST CANCER

s / The Breast 24 S3 (2015) S21–S75 S51 2400 mg per day on days 1 to 21 every 28 days. Fulvestrant combined with capecitabine was administered as 2nd, 3rd, or 4th regimen of MBC following progression of fulvestrant monotherapy in 3 patients, and it was administered as 2nd or 4th regimen following progression of other regimens without fulvestrant in 2 patients. Fulvestrant combined with capecitabine was administered as 2nd, 3rd, or 4th regimen of MBC following progression of fulvestrant monotherapy in 3 patients, and administered as 2nd or 4th regimen following progression of other regimens without fulvestrant in 2 patients. Chemotherapy was an initial treatment in 1 patient with stage IV disease. Best responses were as follows. Partial response (PR) and stable disease (SD) were observed in 3 and 2 patients, respectively. Time to progression (TTP) was 15 months in 1 patient; however, 4 were censored in TTP analysis (3, 4, 7, and 13 months). No grade 3 or 4 adverse events were observed in fulvestrant combined with capecitabine regimen. Grade 2 palmarplantar erythrodysesthesia was observed in 2 patients, in one of whom the dose of capecitabine was reduced. No other grade 2 adverse events were observed. Our retrospective study indicates that fulvestrant combined with capecitabine is effective and well tolerated for patients with ER-positive, HER2-negative MBC. Further analyses will be needed in a prospective study setting.